EXTL2

Across TCGA pan-cancer cohorts, EXTL2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of EXTL2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where EXTL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EXTL2 is over-expressed in tumor, although a few such as LUAD and CCRCC show the opposite, repressed pattern.

COAD, LUAD, and CCRCC are the cancer types where EXTL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EXTL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	III,IV	+0.617	<.001	10	view →
LUAD	Female	II,III,IV	−0.675	<.001	8	view →
CCRCC	Male	All	−0.166	.010	2	view →
LSCC	All	All	−0.160	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

EXTL2–COAD

Open the COAD breakdown →